Glaxo needs long-acting HIV gamble to pay off
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
Gilead challenges Viiv in heavily treated HIV
And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.
Viiv’s HIV success shows PrEP is not everything
Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.
Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
